Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase role of blood pressure and endothelial function

Hypertension

Volumn 31, Issue 6, 1998, Pages 1305-1310

  D'Uscio, Livius V ^a   Shaw, Sidney ^a,b   Barton, Matthias ^a   Lüscher, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angiotensin II; Aorta; Endothelin; Endothelium; Losartan; Verapamil

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(2 HEPTANAMIDOACETAMIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ACETYLCHOLINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; LOSARTAN; NITROPRUSSIDE SODIUM; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HYPERTENSION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM;

EID: 0031864167     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.31.6.1305     Document Type: Article

References (46)

1. Lüscher TF, Vanhoutte PM. The Endothelium: Modulator of Cardiovascular Function. Boca Raton, Fla: CRC Press; 1990:1-215.
2. Dzau VJ. Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. In: Grobecker H, Heusch G, Strauer BE, eds. Angiotensin and the Heart. Darmstadt, Germany: Steinkopff Verlag; 1993:1-14.
3. Teerlink JR. Neurohumoral mechanisms in heart failure: a central role for the renin-angiotensin system. J Cardiovasc Pharmacol. 1996;27:S1-S8.
4. Dubey RK, Jackson EK, Lüscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell: role of cyclic-nucleotides and angiotensin 1 receptors. J Clin Invest. 1995;96:141-149.
5. Boulanger CM, Caputo L, Lévy BI. Endothelial AT1-mediated release of nitric oxide decreases angiotensin II contractions in rat carotid artery. Hypertension. 1995;26:752-757.
6. Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 1995;26:164-170.
7. Hennington BS, Zhang H, Granger JP, Reckelhoff JF. Angiotensin II chronically increases endothelial nitric oxide synthase protein in the kidneys of rats. Hypertension. 1997;30:481. Abstract.
8. Wilcox CS, Welch WJ. Thromboxane mediation of the pressor response to infused angiotensin II. Am J Hypertens. 1990;3:242-249.
9. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
10. Emori T, Hirata Y, Ohta K, Kanno K, Eguchi S, Imai T, Shichiri M, Marumo F. Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension. 1991;18:165-170.
11. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension. 1992;19:753-757.
12. Dubin D, Pratt RE, Cooke JP, Dzau VJ. Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen. J Vasc Med Biol. 1989;1: 13-17.
13. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis. 1989;78:225-228.
14. Paul M, Zintz M, Böcker W, Dyer M. Characterization and functional analysis of the rat endothelin-1 promoter. Hypertension. 1995;25: 683-687.
15. Hahn AWA, Resink TJ, Scott-Burden T, Powell J, Dohi Y, Bühler FR. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul. 1990;1:649-659.
16. Sung CP, Arleth AJ, Storer BL, Ohlstein EH. Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther. 1994;271: 429-437.
17. A-receptor antagonist. Circulation. 1997;96: 1593-1597.
18. Dohi Y, Hahn A, Boulanger CM, Bühler FR, Lüscher TF. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension. 1992;19:131-137.
19. Novosel D, Lang MG, Noll G. Lüscher TF. Endothelial dysfunction in aorta of the spontaneously hypertensive, stroke-prone rat: effects of therapy with verapamil and trandolapril alone and in combination. J Cardiovasc Pharmacol. 1994;24:979-985.
20. Tschudi MR, Criscione L, Novosel D, Pfeiffer K, Lüscher TF. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation. 1994;89: 2212-2218.
21. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
22. Auch-Schwelk W, Katusic ZS, Vanhoutte PM. Thromboxane A2 receptor antagonists inhibit endothelium-dependent contractions. Hypertension. 1990;15:699-703.
23. Auch-Schwelk W, Katusic ZS, Vanhoutte PM. Contractions to oxygen-derived free radicals are augmented in aorta of the spontaneously hypertensive rats. Hypertension. 1989;13:859-864.
24. Rees DD, Palmer RMJ, Hodson HF, Moncada S. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol. 1989;96:418-424.
25. A receptor blockade in angiotensin II-induced hypertension. Hypertension. 1997;29:435-441.
26. Wallenstein S, Zucker CL, Fleiss J. Some statistical methods useful in circulation research. Circ Res. 1980;47:1-9.
27. Rosenthal T, Erlich Y, Rosenmann E, Cohen A. Effects of enalapril. losartan, and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rats. Hypertension. 1997;29: 1260-1264.
28. Küng CF, Moreau P, Takase H, Lüscher TF. L-NAME hypertension alters endothelial and smooth muscle function in rat aorta: prevention by trandolapril and verapamil. Hypertension. 1995;26:744-751.
29. Bakris GL, Bhandaru S, Akerstrom V, Re RN. ACE inhibitor-mediated attenuation of mesangial cell growth: a role for endothelin. Am J Hypertens. 1994;7:583-590.
30. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhausl W, Binder BR. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 1992;267:16066-16068.
31. 2+ antagonists. J Cardiovasc Pharmacol Suppl. 1988;12(suppl 6):S21-S28.
32. Himmel HM, Whorton AR, Strauss HC. Intracellular calcium, currents, and stimulus-response coupling in endothelial cells. Hypertension. 1993; 21:112-127.
33. A-receptors for endothelin regulation. Biochem Biophys Res Commun. 1997;238:861-865.
34. Goerre S, Wenk M, Bartsch P, Lüscher TF, Niroomand F, Hohenhaus E, Oelz O, Reinhart WH. Endothelin-1 in pulmonary hypertension associated with high-altitude exposure. Circulation. 1995;91:359-364.
35. Rajagopalan S, Laursen JB, Borthayre A, Kurz S, Keiser J, S. H, Giaid A, Harrison DG. Role for endothelin-1 in angiotensin II-mediated hypertension. Hypertension. 1997;30:29-34.
36. 2+ antagonists. J Cardiovasc Pharmacol. 1989;13(suppl 5):S32-S35.
37. Yang Z, Bauer E, von Segesser L, Stulz P, Turina M, L̈scher TF. Different mobilization of calcium in endothelin-1-induced contractions in human arteries and veins: effects of calcium antagonists. J Cardiovasc Pharmacol. 1990;16:654-660.
38. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Webb DJ, Rabelink T. Blockade of the endothelin-A receptor increases endogenous NO generation. Circulation. 1997:96(suppl I):I-348. Abstract.
39. Lüscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension. 1986;8:344-348.
40. Mistry M, Nasjletti A. Role of pressor prostanoids in rats with angiotensin II-salt-induced hypertension. Hypertension. 1988;11:758-762.
41. Lin L, Mistry M, Stier C Jr, Nasjletti A. Role of prostanoids in renin-dependent and renin-independent hypertension. Hypertension. 1991;17: 517-525.
42. Spinale FG, Walker JD, Mukherjee R, Iannini JP, Keever AT, Gallagher KP. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits: beneficial effects on left ventricular and myocyte function. Circulation. 1997; 95:1918-1929.
43. Yazaki Y, Yamazaki T. Reversing congestive heart failure with endothelin receptor antagonist. Circulation. 1997;95:1752-1754.
44. Watanabe T, Suzuki N, Shimamoto N, Fujino M, Imada A. Endothelin in myocardial infarction. Nature. 1990;344:114. Letter.
45. Clavell AL, Mattingly MT, Stevens TL, Nir A, Wright S, Aarhus LL, Heublein DM, Burnett JC Jr. Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J Clin Invest. 1996;97:1286-1292.
46. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero O. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role for kinins and angiotensin II type 2 receptors. J Clin Invest. 1997;99: 1926-1935.